Eterna Therapeutics (ERNA) Q1 2026 Earnings
ERNA·Reported May 11, 2026·After market close
Diluted EPS came in at $-6.95 (-208.9% YoY), missed the $-1.95 consensus by $5.00.
Diluted EPS
$-6.95missed by $5.00
Consensus: $-1.95
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Eterna Therapeutics's Q1 2026 earnings report.
Eterna Therapeutics (ERNA) reported Q1 2026 earnings on May 11, 2026 after market close.
Eterna Therapeutics reported diluted EPS of $-6.95 for Q1 2026.
EPS missed the consensus estimate of $-1.95 by $5.00.
Compared to the same quarter a year prior, diluted EPS declined 208.9% from $-2.25.
You can read the 10-Q periodic report (0001493152-26-022276) directly on SEC EDGAR. The filing index links above go to sec.gov.